|
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors Clinical research trials and A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors. A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors clinical trial. Human subjects often get the best healthcare possible for their A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors  A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
For Condition: HIV Infections
Status: Completed
Sponsor(s): Abbott Laboratories ,
Synopsis: The purpose of this study is to see if it is safe and effective to give ABT-378/ritonavir combination plus nevirapine plus two nucleoside transcriptase inhibitors to HIV-infected patients who previously have taken protease inhibitors. This study also examines how the body handles this combination of anti-HIV drugs.
Details:
Eligibility:
Study Type: Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: Antiretroviral regimen containing a protease inhibitor and one or two nucleoside reverse transcriptase inhibitors that has not changed in the last 12 weeks. Patients must have: HIV infection with plasma HIV RNA of at least 1,000 copies/ml and less than or equal to 100,000 copies/ml at screening. Prior Medication: Allowed: Naive to or has had less than 8 weeks of at least one nucleoside reverse transcriptase inhibitor and an acceptable regimen of two nucleoside reverse transcriptase inhibitors. Exclusion Criteria Concurrent Medication: Excluded: - Medications that are contraindicated with ABT-378/ritonavir for the duration of the study, such as midazolam, triazolam, terfenadine, astemizole, cisapride, pimozide, ergotamine and dihydroergotamine. - Over-the-counter medicine or alcohol, without knowledge or permission of the investigator. Patients with the following prior conditions are excluded: - Evidence of acute illness determined by vital signs, physical examination, or laboratory results. - Clinically significant abnormal ECG results. - Positive test result for drug abuse with the exception of cannabis, unless the investigator anticipates cannabis use will interfere with compliance with the study. Prior Medication: Excluded: - Investigational drugs with the exception of Amprenavir within 28 days prior to the initiation of study dosing. - Treatment with a non-nucleoside reverse transcriptase inhibitor. - Treatment with a protease inhibitor different from the current protease inhibitor for more than 6 weeks prior to current regimen. - Treatment with more than one protease inhibitor concurrently. Risk Behavior: Excluded: - Active substance abuse, alcohol abuse, psychiatric illness. - Presumption, by investigator, of poor compliance to regimen.
Total Enrollment:
Location and Contact Information:
Univ of Colorado Health Sciences Ctr
Denver, Colorado, 80262
United States
Infectious Disease Physicians Inc
Annandale, Virginia, 22203
United States
San Francisco Gen Hosp / UCSF AIDS Program
San Francisco, California, 94110
United States
Pacific Oaks Research
Beverly Hills, California, 90211
United States
Rush Presbyterian St Lukes Med Ctr / Sect Infect Dise
Chicago, Illinois, 60612
United States
Duke Univ Med Ctr / Infectious Disease Clinic
Durham, North Carolina, 27710
United States
Univ North Carolina at Chapel Hill / Dept of Medicine
Chapel Hill, North Carolina, 27599
United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, 30308
United States
Univ of Cincinnati Med Ctr / Holmes Div Mail Loc 0405
Cincinnati, Ohio, 452670405
United States
Univ of Pittsburgh
Pittsburgh, Pennsylvania, 152132582
United States
Additional Information:
Study ID Numbers: 285B; M97-765
Study Start Date:
Record last reviewed: April 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004580
Other Hiv Infections Studies:
1. A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
2. A Study of Decreased Mental Function Associated with HIV
3. Evaluation and Natural History of Children with Cancer and AIDS
4. The Effect of Teaching HIV-Infected Patients about HIV and Treatment
5. Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
|
|
|
|
|
|
|
|
